Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of efruxifermin in noninvasively diagnosed NASH/MASH and NAFLD/MASLD
MOH_2024-02-05_013239Phase 3Active, not recruiting
- Sponsor
- Akero Therapeutics
- Start
- Jan 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Placebo with Efruxifermin 50 mg (2 arms). Started Jan 2024; status: active, not recruiting.
02
Drugs
efruxifermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on MOH_2024-02-05_013239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-05_013239.